LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

▤ Summary

LifeMD announced an exclusive collaboration with Halozyme’s Antares Pharma subsidiary to launch a direct-to-patient self-pay program for XYOSTED in July 2026. The program pairs telehealth visits, lab testing, pharmacy fulfillment, and home delivery into a single monthly price for eligible patients in 37 states. LifeMD will act as the exclusive telehealth co-marketing partner, while its pharmacy will be the preferred dispensing channel. The companies plan to expand the program to insurance-covered patients and additional states as telehealth prescribing rules allow.

▦ Linked Companies